Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.

Radiation Toxicity Clinical Trial

Official title:

Randomized Trial to Quantify the Efficacy of the Safetac® Product Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04617730
• Other study ID #: CE3220.
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: January 1, 2021
• Est. completion date: January 1, 2025

Study information

• Verified date: October 2020
• Source: Jules Bordet Institute
• Contact: Gitte Van de Ven, MSc
• Phone: 02 541 3882
• Email: gitte.vandeven[@]bordet.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim is to quantify the efficiency of the Safetac product Mepitel® Film on the prevention of radiodermatitis for cancer patients treated with external beam radiation therapy near the inguinal fold(s). Previous studies have looked into the differences in skin reactions for Mepitel® Film versus hydro-active colloid gel in breast cancer [1, 2] and head and neck cancer [3]. In breast cancer, the prevalence of radiation induced dermatitis has strongly decreased due to of modern radiotherapy techniques and fractionation. In the groin, however, this is not the case, and radiation dermatitis remains an important problem. To the best of our knowledge, no previous study has looked into the efficiency of a prophylactic Mepitel® Film protocol in the inguinal fold. The goal of this study is to evaluate whether the Mepitel® Film offers a lower degree of radiation-induced dermatitis compared to hydro-active colloid gel and thereby challenging the gold standard.

References:

1. Herst, P., Bennett, N., Sutherland, A., Peszynski, R., Paterson, D. and Jasperse, M. (2014). Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients. Radiotherapy and Oncology, 110(1), pp.137-143.

2. Møller, P., Olling, K., Berg, M., Habæk, I., Haislund, B., Iversen, A., Ewertz, M., Lorenzen, E. and Brink, C. (2018). Breast cancer patients report reduced sensitivity and pain using a barrier film during radiotherapy - A Danish intra-patient randomized multicentre study. Technical Innovations & Patient Support in Radiation Oncology, 7, pp.20-25.

3. Wooding, H., Yan, J., Yuan, L., Chyou, T., Gao, S., Ward, I. and Herst, P. (2018). The effect of Mepitel Film on acute radiation-induced skin reactions in head and neck cancer patients: a feasibility study. The British Journal of Radiology, 91(1081), p.20170298.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 35
• Est. completion date: January 1, 2025
• Est. primary completion date: January 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with external beam radiotherapy of the bilateral inguinal nodal region, with at least 25 fractions of 1.8-2Gy per fraction.

Exclusion Criteria:

• Re-irradiation.

• Pregnancy.

• Patients under the age of 18.

• Patients not willing to participate (no informed consent).

Related Conditions & MeSH terms

• Radiation Toxicity
• Radiodermatitis
• Radiotherapy Side Effect

Intervention

Device:
• Mepitel® film
This study is a comparative study between the standard procedure, which is to prescribe a hydro-active colloidal gel called Flamigel® to be applied to the irradiated area, and the use of Mepitel® Film.

Other:
• Flamigel®
The control arm will be treated according to the standard of care.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jules Bordet Institute

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevention of grade 2.5 RTOG radiodermatitis	To evaluate and quantify the influence of the Mepitel® Film dressing on the prevention of patchy moist desquamation (grade 2.5 RTOG) radiodermatitis in the inguinal fold.	Post 25 sessions
Secondary	Time to radiodermatitis apparition	To analyze the time it takes for the patchy moist desquamation (grade 2.5 RTOG) to appear and to evaluate whether it occurs later in the Mepitel® Film group.	At the end of treatment
Secondary	Healing time	To analyze the time that the patchy moist desquamation takes to heal and to evaluate if the Mepitel® film group can heal faster.	3 months post treatment